NCT03100006 (ORION-01) is a Phase 1, PHASE2 clinical trial of Nivolumab in Epithelial Ovarian Cancer, sponsored by National Cancer Centre, Singapore.

Who is sponsoring NCT03100006?

NCT03100006 is sponsored by National Cancer Centre, Singapore.

What drugs are being tested in NCT03100006?

Interventions in NCT03100006: Nivolumab, Oregovomab.

What condition does NCT03100006 study?

NCT03100006 studies Epithelial Ovarian Cancer.

Is NCT03100006 still recruiting?

NCT03100006 is currently terminated. Last updated 13 June 2022.

Last reviewed 2022-06-13 · How we verify

NCT03100006: ORION-01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Terminated Phase 1, PHASE2 Last updated 13 June 2022

What this trial tests

Phase 1, PHASE2 trial testing Nivolumab in Epithelial Ovarian Cancer in 13 participants. Terminated before completion.

Timeline

22 February 2017

Primary endpoint
7 June 2019

17 April 2020

Quick facts

Lead sponsor	National Cancer Centre, Singapore
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	22 February 2017
Primary completion	7 June 2019
Estimated completion	17 April 2020
Sites	1 location across Singapore

Drugs / interventions tested

Nivolumab (nivolumab) — full drug profile →
Oregovomab — full drug profile →

Conditions studied

Epithelial Ovarian Cancer — all drugs for Epithelial Ovarian Cancer →

Sponsor

National Cancer Centre, Singapore

Who can join

Adults 21 to 99, female only, with Epithelial Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to characterize the safety and tolerability, identify a recommended dose for expansion (RDE) / recommended phase II dose (RP2D), pharmacodynamics, and antitumor activity of Oregovomab vaccination in combination with Nivolumab as a novel combinatorial immunotherapeutic strategy in in female patients with recurrent epithelial ovarian cancer (EOC) who progressed after two or more prior lines of cytotoxic chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in ovarian cancer therapy.
Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. · · 2018 · cited 417× · PMID 29249039 · DOI 10.1007/s00280-017-3501-8
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.
Yang C, Xia BR, Zhang ZC, Zhang YJ, et al · · 2020 · cited 246× · PMID 33123161 · DOI 10.3389/fimmu.2020.577869
Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
Revythis A, Limbu A, Mikropoulos C, Ghose A, et al · · 2022 · cited 73× · PMID 35886427 · DOI 10.3390/ijerph19148577
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.
Maiorano BA, Maiorano MFP, Lorusso D, Maiello E. · · 2021 · cited 60× · PMID 34503248 · DOI 10.3390/cancers13174438
Role of tumor microenvironment in ovarian cancer pathobiology.
Ghoneum A, Afify H, Salih Z, Kelly M, et al · · 2018 · cited 58× · PMID 29854318 · DOI 10.18632/oncotarget.25126
Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.
Ghoneum A, Almousa S, Warren B, Abdulfattah AY, et al · · 2021 · cited 53× · PMID 33476723 · DOI 10.1016/j.semcancer.2020.12.024
Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities.
Ghoneum A, Afify H, Salih Z, Kelly M, et al · · 2018 · cited 46× · PMID 30133163 · DOI 10.1002/cam4.1741
Development of Therapeutic Vaccines for Ovarian Cancer.
Chow S, Berek JS, Dorigo O. · · 2020 · cited 28× · PMID 33167428 · DOI 10.3390/vaccines8040657

Verify or expand the search:

Other trials of Nivolumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting

Other recruiting trials for Epithelial Ovarian Cancer

Currently open trials in the same condition.

NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07480954 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) · Phase 1, PHASE2 · recruiting
NCT07218809 — AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Can · Phase 3 · recruiting
NCT07495397 — Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targete · NA · recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting

Other National Cancer Centre, Singapore trials

Trials by the same sponsor.

NCT07428356 — Histotripsy for Ablation of Liver Tumours in Asia · NA · recruiting
NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting
NCT07116161 — Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore · NA · recruiting
NCT06977360 — Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solutio · NA · recruiting
NCT06766058 — Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03100006 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Centre, Singapore
Last refreshed: 13 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03100006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing